Dosing & Uses
Dosage Forms & Strengths
40 mg/day PO initially; titrated to 20-80 mgday PO, depending on response; patients with volume depletion should receive the lower dosage initially, under close supervision
- Generally, adjust dosage monthly; adjust more aggressively in high-risk patients
- Also given in combination with hydrochlorothiazide (Micardis HCT) or amlodipine (Twynsta)
Cardiovascular Risk Reduction
80 mg/day PO; whether dosages <80 mg/day reduce risk of cardiovascular morbidity or mortality is unknown
Renal impairment: Dosage adjustment not necessary; hemodialysis (HD) patients at risk for orthostatic hypotension
Hepatic impairment: Initiate at low dosage; titrate slowly; monitor
<18 years old: Safety and efficacy not established
20 mg/day PO initially; maintenance: 20-80 mg/day
Cardiovascular Risk Reduction
80 mg/day PO
Serious - Use Alternative
Significant - Monitor Closely
Upper respiratory tract infection (URTI) (7%)
Back pain (3%)
Chest pain (1%)
Black Box Warnings
Discontinue as soon as possible when pregnancy is detected; drug affects renin-angiotensin system, causing oligohydramnios, which may result in fetal injury or death
Hypersensitivity (anaphylaxis, angioedema)
Pregnancy (2nd and 3rd trimesters); significant risk of fetal or neonatal morbidity and mortality (see Black Box Warnings)
Bilateral renal artery stenosis
Do not coadminister with aliskiren in patients with diabetes
Correct any volume or salt depletion before initiating therapy; observe for signs and symptoms of hypotension
Less blood pressure response in black patients than in white patients
Risk of sensitivity reactions, including anaphylactoid reactions or angioedema
Congestive heart failure (CHF); risk of renal dysfunction
Renal impairment, obstructive biliary disease, or hepatic impairment
Dual blockade of the renin-angiotensin system with angiotensin-receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, or aliskiren is associated with increased risk of hypotension, hyperkalemia, and altered renal function (including acute renal failure) in comparison with monotherapy
Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy; avoid combined use of RAS inhibitors; closely monitor blood pressure, renal function and electrolytes in patients on benazepril and other agents that affect the RAS
Not for coadministration with aliskiren in patients with diabetes; avoid use of aliskiren with benazepril in patients with renal impairment (GFR <60 ml/min/1.73 m2)
Pregnancy & Lactation
Pregnancy category: 1st trimester, C; 2nd and 3rd trimesters, D
Lactation: Not known whether drug is excreted in breast milk; avoid using
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Angiotensin II receptor blocker; inhibits vasoconstrictor and aldosterone-secreting effects of angiotensin II
Onset: 1-2 hr
Duration: <24 hr
Peak plasma time: 0.5-1 hr
Protein bound: >99.5%
Vd: 500 L
Metabolized in liver to inactive metabolite
Half-life: 24 hr
Dialyzable: No (HD)
Excretion: Feces (>97%), urine (small amount)
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.